Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07096453 · ClinicalTrials.gov registry record · Phase 1
CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients
A Phase 1 study of Kidney Transplant; Complications and CMV, sponsored by University of Minnesota.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07096453: Recruiting Phase 1 study of Kidney Transplant; Complications and CMV, sponsored by University of Minnesota.
NCT07096453 is a Phase 1 study of Kidney Transplant; Complications and CMV that is actively recruiting participants, run by University of Minnesota. The registered enrollment target is 30 participants, below the 120-participant average among 19 other Kidney Transplant; Complications trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07096453, a Phase 1 study of Kidney Transplant; Complications and CMV, is actively recruiting participants, sponsored by University of Minnesota.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to study how CMVIG interacts with the body and to see if it might work to prevent kidney transplant patients from becoming infected with CMV.
Primary Outcome
Measured with ELISA testing
Conditions Studied
Interventions
- DRUG Cytogam
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-10-02 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
What NCT07096453 shows while recruiting
NCT07096453 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 120-participant average among 19 other Kidney Transplant; Complications trials with a reported enrollment target (75% lower).
The record links to 2 conditions, with Kidney Transplant; Complications appearing as the primary indexed condition, and to 1 intervention - of which Cytogam is the first listed.
NCT07096453 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT07096453 about?
NCT07096453 is a clinical study titled "CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients". The purpose of this study is to study how CMVIG interacts with the body and to see if it might work to prevent kidney transplant patients from becoming infected with CMV.
What is the current status of trial NCT07096453?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-10-02. Estimated completion is 2027-08.
What conditions does trial NCT07096453 study?
This clinical trial studies the following conditions: Kidney Transplant; Complications, CMV.
What interventions are being tested in trial NCT07096453?
The interventions under investigation include: Cytogam (DRUG).
Who is sponsoring clinical trial NCT07096453?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07096453 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplant; Complications
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07096453's enrollment target sits among peer trials
30 16th of 19 higher than 3 of 19 other Kidney Transplant; Complications trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Transplant; Complications trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Delayed Tolerance Through Mixed Chimerism
ACTIVE NOT RECRUITING · Phase 1
-
Immune Registry for BK in Kidney Transplant Recipients
RECRUITING
-
Feasibility Study for the Comprehensive Overweight/Obesity Management Pre-Kidney Transplant (COMPKT) Program
RECRUITING · NA
-
The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study
RECRUITING · Phase 2
-
Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI